

Supplemental material 1

List of drugs for inclusion of patients in the extended population

ATC	Name
N06AX22	Agomelatin, Valdoxan
B01AF02	Apixaban, Eliquis
B01AE07	Dabigatran, Pradaxa
A10BK01	Dapagliflozin, Forxiga
A10BJ05	Dulaglutid, Trulicity
B01AF03	Edoxaban, Lixiana
C03DA04	Eplerenon, Inspra
M04AA03	Febuxostat, Adenuric
C01EB17	Ivabradin, Procoralan
N06BA12	Lisdexamfetamin, Elvanse
N03AX16	Pregabalin, Lyrica
B01AF01	Rivaroxaban, Xarelto
C09DX04	Sacubitril/Valsartan, Entresto
A10BH03	Saxagliptin, Onglyza
A10BH01	Sitagliptin, Januvia
N02AX06	Tapentadol, Palexia
B01AC24	Ticragelor, Brillique
C10BA02	Ezetimib/Simvastatin, Inegy
N02AA55	Oxycodon/Naloxon, Targin
M05BX04	Denosumab, Prolia
N06AX21	Duloxetine, Cymbalta
A10BK02	Canagliflozin, Invokana
A10BK03	Empagliflozin, Jardiance
L04AB01	Etanercept, Enbrel
N06BA09	Atomoxetine, Strattera
N07XX09	Dimethylfumarat, Tecfidera
C01BD07	Dronedaron, Multaq
R03AC18	Indacaterol/Glycopyrronium, Ultibro Breezhaler
A10BJ02	Liraglutid, Victoza
B01AC22	Prasugrel, Efient
A10AE04	Insulin glargin, Toujeo
R03AL06	Tiotropium/Olodaterol, Spiolto
R03AL03	Umeclidinium/Vilanterol, Anoro
G04BD08	Solifenacin, Vesikur

Notes: This list was developed within the WirtMed study and comprises drugs with a high price and/or unsure or unproved medical benefit for patients.